These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25138679)

  • 1. Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatin.
    Lee HI; Choi CI; Sa JH; Lee YJ; Bae JW; Jang CG; Lee SY
    Int J Clin Pharmacol Ther; 2014 Nov; 52(11):981-5. PubMed ID: 25138679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin.
    He YJ; Zhang W; Tu JH; Kirchheiner J; Chen Y; Guo D; Li Q; Li ZY; Chen H; Hu DL; Wang D; Zhou HH
    Drug Metab Dispos; 2008 Aug; 36(8):1453-6. PubMed ID: 18443034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
    Wen J; Xiong Y
    J Clin Pharm Ther; 2010 Feb; 35(1):99-104. PubMed ID: 20175818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
    Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
    Chung JY; Cho JY; Yu KS; Kim JR; Oh DS; Jung HR; Lim KS; Moon KH; Shin SG; Jang IJ
    Clin Pharmacol Ther; 2005 Oct; 78(4):342-50. PubMed ID: 16198653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin.
    Choi CI; Lee YJ; Lee HI; Kim BH; Kim MJ; Jang CG; Bae JW; Lee SY
    Xenobiotica; 2012 May; 42(5):496-501. PubMed ID: 22077103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Saito T; Ogawa S; Kojima J
    J Pharm Pharmacol; 2005 Oct; 57(10):1305-11. PubMed ID: 16259759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
    Hua WJ; Hua WX; Fang HJ
    Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
    Deng JW; Song IS; Shin HJ; Yeo CW; Cho DY; Shon JH; Shin JG
    Pharmacogenet Genomics; 2008 May; 18(5):424-33. PubMed ID: 18408565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease.
    Li Z; Tian S; Wu Z; Xu X; Lei L; Li Y; Wang B; Huang Y
    J Ethnopharmacol; 2021 Nov; 280():114469. PubMed ID: 34329714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Nakai D; Nakagomi R; Saito M; Tokui T; Kojima J
    Arzneimittelforschung; 2004; 54(7):382-8. PubMed ID: 15344842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin.
    Hu M; Mak VW; Yin OQ; Chu TT; Tomlinson B
    Drug Metab Pharmacokinet; 2013; 28(2):104-8. PubMed ID: 22850760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.
    Chen Y; Zhang W; Huang WH; Tan ZR; Wang YC; Huang X; Zhou HH
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1933-8. PubMed ID: 23831870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.
    Jung JA; Noh YH; Jin S; Kim MJ; Kim YH; Jung JA; Lim HS; Bae KS
    Clin Ther; 2012 Apr; 34(4):958-65. PubMed ID: 22410289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin - pharmacological profile from early phase studies.
    Catapano AL
    Atheroscler Suppl; 2010 Dec; 11(3):3-7. PubMed ID: 21193152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.
    Cho CK; Mo JY; Ko E; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
    Arch Pharm Res; 2024 Feb; 47(2):95-110. PubMed ID: 38159179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):139-46. PubMed ID: 15159445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
    König J; Klatt S; Dilger K; Fromm MF
    Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.